Table 5.
Event | DFN-15 120 mg (n = 15) |
DFN-15 180 mg (n = 15) |
DFN-15 240 mg (n = 16) |
Oral capsules 400 mg (n = 15) |
---|---|---|---|---|
Subjects with one or more AE | 0 | 0 | 1 (6.3) | 0 |
Investigations | 0 | 0 | 1 (6.3) | 0 |
Hemoglobin decreased | 0 | 0 | 1 (6.3) | 0 |
Occult blood positive | 0 | 0 | 1 (6.3) | 0 |
Data are presented as n (%)
AE adverse event